Strategic partnerships OncoSec has a history of collaboration with major pharma partners such as Merck on KEYNOTE programs, presenting a strong pathway for co-development or pivotal trial collaborations to expand TAVO usage in combination regimens.

Clinical expansion Ongoing Phase II/Phase 2b trials in challenging indications like metastatic melanoma and triple-negative breast cancer suggest opportunity for sponsorships, investigator-initiated studies, or broader indication exploration with checkpoint inhibitors or other immunotherapies.

Regulatory incentives TAVO has FDA Orphan Drug and Fast-Track Designations for metastatic melanoma, signaling possible accelerated pathways and priority review support that could be leveraged in financing, milestone-based deals, or milestone-driven collaborations.

Patient access The company’s focus on intratumoral IL-12 delivery and immunotherapy reduces systemic exposure, which can appeal to healthcare systems seeking treatments with favorable safety profiles for hard-to-treat solid tumors.

Financial levers With a modest revenue base and recent executive leadership changes, there may be appetite for strategic investments, licensing, or partnerships that provide operating runway for expansion into additional tumor indications and DNA-encoded therapeutics.